Company Overview and News

 
New Strong Buy Stocks for April 4th

2017-04-04 zacks
Bravo Brio Restaurant Group, Inc. (BBRG - Free Report) : This owner and operator of Italian restaurants in the United States has witnessed the Zacks Consensus Estimate for its current year earnings surging 4.1% over the last 30 days.
Upvote Downvote

 
Increased Earnings Estimates Seen for Enerplus (ERF): Can It Move Higher?

2016-03-31 zacks
Enerplus Corporation (ERF - Snapshot Report) is an oil and gas producer that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ERF’s earnings for the coming quarter and year.
Upvote Downvote

 
Why You Shouldn't Bet Against Enerplus (ERF) Stock

2016-03-28 zacks
One stock that might be an intriguing choice for investors right now is Enerplus Corporation (ERF - Snapshot Report). This is because this security in the Oil Exploration and Production space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Upvote Downvote

 
Will Enerplus (ERF) Continue to Surge Higher?

2016-03-17 zacks
As of late, it has definitely been a great time to be an investor in Enerplus Corporation (ERF - Snapshot Report). The stock has moved higher by 15.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
Upvote Downvote

 
Agilent (A) & Eurofins Team Up for SureVector Expansion

2016-03-14 zacks
Agilent Technologies Inc.(A - Analyst Report) has collaborated with Eurofins Genomics to expand Agilent’s SureVector cloning system. Under this pact, Agilent will use Eurofins’ technology to create custom components and assemble plasmid service for its SureVector next-generation cloning kits.
Upvote Downvote

 
Agilent Technologies Inc. And Eurofins Genomics Collaborate To Expand Surevector Cloning System

2016-03-11 devicespace
SANTA CLARA, Calif. & MILAN--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) and Eurofins Genomics today announced that Agilent plans to offer custom components and an assembled plasmid service for Agilent’s SureVector next-generation cloning kits through a collaboration with Eurofins. Agilent will also offer a set of catalog components for its leading-edge SureVector cloning kits, enabling the creation of over 1 million different cloning vectors.
Upvote Downvote

 
Eurofins Microbiology Opens State-of-the-Art Laboratory in Louisville, KY

2016-02-22 prnewswire
DES MOINES, Iowa, Feb. 22, 2016 /PRNewswire/ -- Eurofins Microbiology, a global leader in bioanalytical testing...
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...